Melitracene

Structural formula
General
Non-proprietary name	Melitracene
other names	N , N -dimethyl-3- (10,10-dimethyl-9,10-dihydroanthracen-9-ylidene) propylamine
Molecular formula	C 21 H 25 N; C 21 H 25 N · HCl (hydrochloride);
External identifiers / databases
EC number	225-858-5
ECHA InfoCard	100.023.507
PubChem	25382
ChemSpider	23697
DrugBank	DB13384
Wikidata	Q411251
Drug information
ATC code	N06 AA14 ; N06 CA02 ;
Drug class	antidepressant
properties
Molar mass	291.43 g · mol -1 ; 327.90 g mol −1 (hydrochloride);
Physical state	firmly
Melting point	245–248 ° C (melitracen hydrochloride)
safety instructions
	Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS hazard labeling ; no classification available
Toxicological data	170 mg kg −1 ( LD 50 , rat , oral ) ; 315 mg kg −1 ( LD 50 , mouse , oral ) ; 52 mg kg −1 ( LD 50 , mouse , iv ) ; 170 mg kg −1 ( LD 50 , rat , oral , hydrochloride) ; 315 mg kg −1 ( LD 50 , mouse , oral , hydrochloride) ; 52 mg kg −1 ( LD 50 , mouse , iv , hydrochloride) ;
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Melitracen is a tricyclic antidepressant with the pharmacological properties characteristic of this group. It is particularly similar to amitriptyline . In doses less than 150 mg, it is non- sedating .

Melitracen was patented by Kefalas A / S in 1963 and is used in Europe together with the neuroleptic flupentixol as a combination preparation in the drug Deanxit ^® .

application

Melitracen is used in fixed combination with flupentixol ( Deanxit ^® ; 10 mg melitracen and 0.5 mg flupentixol) for the treatment of mild to moderate states of depressive inhibition and anxiety. Deanxit has a mood-enhancing and anxiety-relieving effect and is suitable for the treatment of mild to moderate depression , which is characterized by anxiety , loss of the ability to be happy, fruitless brooding , fear of failure and feelings of guilt . Also used to treat trigeminal - Neuralgia , neuroses and aphthous ulcers combining Melitracen / flupentixol was proposed.

In Germany there are no drugs with the medicinal substance melitracen on the market.

Side effects

The adverse effects include dry mouth, accommodation disorders, tachycardia , hyperhidrosis and orthostatic complaints.

Manufacturing

Melitracene is synthesized in several stages starting from anthrone .

Individual evidence

↑ ^a ^b Entry on Melitracen. In: Römpp Online . Georg Thieme Verlag, accessed on September 29, 2014.
↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
^ ^A ^b ^c ^d ^e ^f ^g A. Kleemann , J. Engel, B. Kutscher, D. Reichert: Pharmaceutical Substances - Synthesis, Patents, Applications , 4th edition, Thieme-Verlag, Stuttgart 2000, ISBN 978-1-58890 -031-9 .
↑ ^a ^b H. Hager: Hager's handbook of pharmaceutical practice . Follow. 1-3, Springer, 1999, ISBN 3-540-62646-8 .

[RÖMPP_Online-1] Entry on Melitracen. In: Römpp Online . Georg Thieme Verlag, accessed on September 29, 2014.

[NV-2] This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.

[Kleemann-3] A ^b ^c ^d ^e ^f ^g A. Kleemann , J. Engel, B. Kutscher, D. Reichert: Pharmaceutical Substances - Synthesis, Patents, Applications , 4th edition, Thieme-Verlag, Stuttgart 2000, ISBN 978-1-58890 -031-9 .

[Hager-4] H. Hager: Hager's handbook of pharmaceutical practice . Follow. 1-3, Springer, 1999, ISBN 3-540-62646-8 .